nature portfolio

Corresponding author(s):

Double-blind peer review submissions: write DBPR and your manuscript number here instead of author names. Changcheng Xu

Last updated by author(s): YYYY-MM-DD 2021-09-07

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our Editorial Policies and the Editorial Policy Checklist.

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

~				
5	ta:	tic	11	\sim

n/a	Confirmed
	$oxed{oxed}$ The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	🔀 A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
X	A description of all covariates tested
X	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
\times	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
X	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection

Provide a description of all commercial, open source and custom code used to collect the data in this study, specifying the version used OR DNA was sequenced on a HiSeq2500 (Illumina) platform, qRT-PCR data were collected using the BIO-Rad CFX Manager. Image J 1.52V for image analysis.

Data analysis

ProMicrosoft Excel 2019 GraphPad Prism 8 were used for statistical analysis to analyse the data in this study, specifying the version used OR state that no software was used

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.

Data

Policy information about <u>availability of data</u>

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Provide ythe data that support the fingdings of this study are available within the paper and its supplementary information. The source data is provided as a Source Data File.

Field-specific reporting

Please select the one below that is the best fit for your researc	ch. If you are not sure, read the appr	ropriate sections before making your selection.
---	--	---

X Life sciences ☐ Behavioural & social sciences ☐ Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size PNo sample size reale ila

No sample size calculation were performed. All sample size was determined to be sufficient based on the consistency a magnitude of measurements. wAll replicates represent biological independent samples. The exat sample size for each experiment was describe in the figure legends and figures.

legends and figur

Describe any data exclusions. If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale bNo; data was excluded from the analysis on criteria were pre-established.

Replication

Data exclusions

Describe the measures taken to verify the reproducibility of the experimental findings. If all attempts at replication were successful, confirm this OR if there are any findings that were not replicated or cannot be reproduced, note this and describe why.

Randomization

Describe how samples/organisms/narticipants were allocated into experimental groups. If allocation was not random, describe how covariates Measurements and samplings of plant materials were randomly performed for our data collection and analysis.

Were contail replicates were carried out at the same time. All an why.

Blinding

Describe whether the investigators were blinded to group allocation during data collection and/or analysis. If blinding was not possible, describ Blinding Was not relevant to this study because all data are objective udy.

Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).

Research sample

State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.

Sampling strategy

Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.

Data collection

Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.

Timing

Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.

Data exclusions

If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.

Non-participation

State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.

Randomization

If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.

Research sample

Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National

Research sample	(Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.						
Sampling strategy	Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.						
Data collection	Describe the data collection procedure, including who recorded the data and how.						
Timing and spatial scale	Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken						
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.						
Reproducibility	Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.						
Randomization	Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.						
Blinding	Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.						
Did the study involve field	d work? Yes No						
Field work collec	tion and transport						
Field conditions	Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).						
Location	State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).						
Access & import/export	Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).						
Disturbance	Describe any disturbance caused by the study and how it was minimized.						
We require information from a	n/a Involved in the study ChIP-seq Flow cytometry MRI-based neuroimaging						
□ Dual use research o Antibodies	f concern						
Antibodies used	Description of Patition of the Studies of the Studi						
Validation	https://www.takarabio.com/products/antibodies-and-elisa/fluorescent-protein-antibodies/green-fluorescent-protein-antibodies?catalog=632569 Des Coar anti-moliserigo FIRF-6666 garten secondarily antibodies of the fluorescent fluorescen						
Eukaryotic cell lin	es						

Policy information about <u>cell lines</u>

Cell line source(s)

State the source of each cell line used.

Authentication

Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.

Mycoplasma contamination

Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.

Commonly misidentified lines (See ICLAC register)

Name any commonly misidentified cell lines used in the study and provide a rationale for their use.

Palaeontology and Archaeology

Specimen provenance

Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information). Permits should encompass collection and, where applicable, export.

Specimen deposition

Indicate where the specimens have been deposited to permit free access by other researchers.

Dating methods

If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.

Tick this box to confirm that the raw and calibrated dates are available in the paper or in Supplementary Information.

Ethics oversight

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals

For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.

Wild animals

Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.

Field-collected samples

For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.

Ethics oversight

Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Human research participants

Policy information about studies involving human research participants

Population characteristics

Describe the covariate-relevant population characteristics of the human research participants (e.g. age, gender, genotypic information, past and current diagnosis and treatment categories). If you filled out the behavioural & social sciences study design questions and have nothing to add here, write "See above."

Recruitment

Describe how participants were recruited. Outline any potential self-selection bias or other biases that may be present and how these are likely to impact results.

Ethics oversight

Identify the organization(s) that approved the study protocol.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Clinical data

Policy information about clinical studies

All manuscripts should comply with the ICMJE guidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.

Clinical trial registration Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.

Study protocol Note where the full trial protocol can be accessed OR if not available, explain why.

Outcomes Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

Dual use research of concern

Policy information about <u>dual use research of concern</u>

	_			ᆈ	_
$\overline{}$	_	/ –	r	7	\

Software

repository, provide accession details.

	Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:					
No Yes Public health National security Crops and/or livest Ecosystems Any other significa						
Experiments of concer	n					
Does the work involve an	y of these experiments of concern:					
Confer resistance to Enhance the virule Increase transmiss Alter the host rang Enable evasion of Enable the weapor Any other potential ChIP-seq Confirm that both rav	to render a vaccine ineffective of therapeutically useful antibiotics or antiviral agents ince of a pathogen or render a nonpathogen virulent bility of a pathogen e of a pathogen liagnostic/detection modalities ization of a biological agent or toxin lly harmful combination of experiments and agents or and final processed data have been deposited in a public database such as GEO. e deposited or provided access to graph files (e.g. BED files) for the called peaks.					
Data access links May remain private before publication. For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" provide a link to the deposited data.						
Files in database submiss	on Provide a list of all files available in the database submission.					
Genome browser session (e.g. UCSC) Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents enable peer review. Write "no longer applicable" for "Final submission" documents.						
Methodology						
Replicates	Describe the experimental replicates, specifying number, type and replicate agreement.					
Sequencing depth	Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.					
Antibodies	Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.					
Peak calling parameters	Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.					
Data quality	Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichments					

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community

Flow Cytometry

 	_	 •	_	7	_	_	•	•	•	_	_	_

PIOLS				
Confirm that:				
The axis labels state the mark	ker and fluorochrome used (e.g. CD4-FITC).			
The axis scales are clearly vis	ible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).			
All plots are contour plots wi	th outliers or pseudocolor plots.			
A numerical value for number	er of cells or percentage (with statistics) is provided.			
Methodology				
Sample preparation	Describe the sample preparation, detailing the biological source of the cells and any tissue processing steps used.			
Instrument	Identify the instrument used for data collection, specifying make and model number.			
Software	Describe the software used to collect and analyze the flow cytometry data. For custom code that has been deposited into a community repository, provide accession details.			
Cell population abundance	Describe the abundance of the relevant cell populations within post-sort fractions, providing details on the purity of the samples and how it was determined.			
Gating strategy	Describe the gating strategy used for all relevant experiments, specifying the preliminary FSC/SSC gates of the starting cell population, indicating where boundaries between "positive" and "negative" staining cell populations are defined.			
Tick this box to confirm that	a figure exemplifying the gating strategy is provided in the Supplementary Information.			
Magnetic resonance in	maging			
Experimental design				
Design type	Indicate task or resting state; event-related or block design.			
Design specifications	Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.			
Behavioral performance measur	State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).			
Acquisition				
Imaging type(s)	Specify: functional, structural, diffusion, perfusion.			
Field strength	Specify in Tesla			
Sequence & imaging parameters	Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.			
Area of acquisition	State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.			
Diffusion MRI Used	Not used			
Preprocessing				
Preprocessing software	Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).			
Normalization	If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for transformation OR indicate that data were not normalized and explain rationale for lack of normalization.			
Normalization template	Describe the template used for normalization/transformation, specifying subject space or group standardized space (e.g. original Talairach, MNI305, ICBM152) OR indicate that the data were not normalized.			
Noise and artifact removal Describe your procedure(s) for artifact and structured noise removal, specifying motion parameters, tissue signals and physiological signals (heart rate, respiration).				

Volume censoring	Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.					
Statistical modeling & infere	nce					
Model type and settings	Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).					
Effect(s) tested	Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.					
Specify type of analysis: W	hole brain ROI-based Both					
Statistic type for inference (See Eklund et al. 2016)	Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.					
Correction	Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).					
Models & analysis						
n/a Involved in the study						
Functional and/or effective	e connectivity					
Graph analysis						
Multivariate modeling or p	predictive analysis					

Functional and/or effective connectivity

Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).

Graph analysis

Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).

Multivariate modeling and predictive analysis

 $Specify\ independent\ variables,\ features\ extraction\ and\ dimension\ reduction,\ model,\ training\ and\ evaluation\ metrics.$